logo





The Quotes are Powered By Forexpros, the Forex, Futures, and Stock Markets Portal.




Companies News
    Advertisement







Karo Bio announced it has achieved first milestone in Pfizer collaboration

Thursday, 05 September 2013
The collaboration between Karo Bio AB and Pfizer Inc. has successfully resulted in a significant achievement within the RORgamma project triggering the first milestone payment to Karo Bio.

In a press release, Karo Bio AB writes that the purpose of the collaboration is to develop drugs for treatment of autoimmune diseases.

“The teams from Karo Bio and Pfizer have enjoyed an excellent interaction and relationship which has helped meet this goal. This achievement clearly demonstrates the value Karo Bio brings to its partners in the area of nuclear receptor drug discovery”, says Karo Bio’s CEO Per Bengtsson.

The collaboration that started in December 2011, aims to discover and develop novel small molecule RORgamma modulators for the treatment of autoimmune diseases. The nuclear hormone receptor RORgamma is a novel attractive target for the treatment of autoimmune diseases like rheumatoid arthritis, multiple sclerosis and psoriasis. RORgamma directly controls the production and secretion of the cytokine IL-17, a major contributor to inflammation. The receptor’s key role in driving disease pathology has been implicated in clinical trials using monoclonal antibodies that neutralize IL-17 activity.





Print Friendly and PDF